Business Context and Reporting Period
Company: Bioaffinity Technologies, Inc. (BIAF)
Filing Type: Form 8-K (Current Report)
Date of Report: September 1, 2026
Reporting Period: Single event date (September 1, 2026)
Business Context: The registrant is an emerging growth company incorporated in Delaware, trading on the Nasdaq Capital Market. The filing reports a corporate event regarding the advancement of its CyPath® Lung test for lung cancer patient surveillance.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This Form 8-K is a current report regarding a specific corporate event and does not contain financial statements or performance metrics.
Material Changes
Item 8.01 (Other Events): On September 1, 2026, the company announced it is advancing the potential application of its CyPath® Lung test specifically for the surveillance of lung cancer patients. This represents a strategic development in the company's product pipeline rather than a financial change.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates a press release (Exhibit 99.1) detailing the advancement of the CyPath® Lung test. No specific financial guidance, quantitative outlook, or new risk factors were disclosed in the text of this report.
Investor Verification Checklist
- Review the attached press release (Exhibit 99.1) for specific details on the CyPath® Lung test advancement.
- Verify the current status of the CyPath® Lung test regulatory approvals or clinical trial phases.
- Check subsequent filings for any financial impact or capital requirements related to this product advancement.
- Confirm the company's continued status as an emerging growth company and its compliance with Nasdaq listing standards.